Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 73
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Dow Rises 217 Points As U.S. Stocks Notch Solid Gains
U.S. stocks came off their session highs on Thursday, but the main benchmarks still closed with solid gains.
Top Equities Stories Of The Day
Tech Stocks Rise Ahead Of Microsoft, Amazon Earnings
Stifel Financial to Hire Two Former Merrill Lynch Advisers
Correction to AT&T Earnings Preview Story
Microsoft Braces for Another Nokia Hit--Earnings Preview
Kyle Bass: Still Bullish on GM, Despite Recall Issue -CNBC
U.S. Hot Stocks: Hot Stocks to Watch
U.S. Stock Futures Hover Near Even
U.S. Hot Stocks: Hot Stocks to Watch
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 183144 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist